Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Compound Glycyrrhizin Injection market was valued at USD 346.8 million in 2024 and is projected to reach USD 451.2 million by 2032, exhibiting a CAGR of 3.4% during the forecast period. The U.S. market size is estimated at USD 45.2 million in 2024, whereas China is projected to dominate, reaching USD 122.5 million by 2032.
Compound Glycyrrhizin Injection is a hepatoprotective drug formulation primarily composed of glycyrrhizin, cysteine, and glycine. It is administered intravenously to treat chronic liver diseases, including hepatitis, by exerting anti-inflammatory and hepatocyte-membrane-stabilizing effects. Because of its efficacy in managing liver dysfunction, this injectable formulation is a critical therapeutic option in regions with high incidences of liver disease.
Market growth is largely driven by the rising global prevalence of liver disorders, particularly hepatitis and non-alcoholic fatty liver disease (NAFLD). However, the market faces challenges such as pricing pressures and competition from alternative oral hepatoprotective agents. Furthermore, strategic initiatives by key players, including Cisen Pharmaceutical and CSPC OUYI Pharmaceutical, to expand their geographical footprint are expected to fuel market expansion. The market remains consolidated, with the top five players, including Shanxi PUDE Pharmaceutical and Beijing Kawin Technology Share-Holding, holding a significant revenue share.
Rising Prevalence of Chronic Liver Diseases
The global increase in chronic liver conditions, including hepatitis, non-alcoholic fatty liver disease (NAFLD), and drug-induced liver injury, is a primary driver for the Compound Glycyrrhizin Injection market. Glycyrrhizin, derived from licorice root, has recognized anti-inflammatory and hepatoprotective properties, making it a key therapeutic agent in managing these conditions. The growing patient pool requiring liver protection therapy directly fuels demand.
Integration into Standard Treatment Protocols
Compound Glycyrrhizin Injection is increasingly being incorporated into clinical guidelines, particularly in the Asia-Pacific region, as an adjunctive therapy. Its efficacy in reducing liver enzyme levels and improving liver function tests supports its adoption alongside conventional treatments, driving market growth in hospital and clinical settings.
The established safety profile and low incidence of severe adverse effects compared to some synthetic alternatives make it a preferred choice for long-term management.
Furthermore, the expansion of healthcare infrastructure in emerging economies is increasing accessibility to advanced hepatology treatments, thereby propelling market expansion.
MARKET CHALLENGES
Stringent Regulatory Hurdles
Despite its established use, Compound Glycyrrhizin Injection faces rigorous regulatory scrutiny in Western markets like North America and Europe. As a botanical drug product, it must meet extensive safety, efficacy, and quality standardization requirements, which can delay approvals and limit geographic expansion.
Other Challenges
Competition from Synthetic Alternatives
The market faces significant competition from a range of synthetic hepatoprotective drugs and newer biologic therapies, which can offer targeted mechanisms of action and are often backed by robust clinical trial data from large pharmaceutical companies.
Supply Chain Vulnerabilities
The reliance on the cultivation and extraction of licorice root introduces supply chain risks. Factors such as climate change, agricultural yield fluctuations, and geopolitical issues in key sourcing regions can impact the consistency and cost of raw materials.
Potential Side Effects and Usage Limitations
The use of glycyrrhizin is associated with potential side effects, notably pseudoaldosteronism, which can lead to hypertension and hypokalemia with prolonged or high-dose use. These safety concerns act as a significant restraint, prompting cautious prescribing practices and limiting its application in patients with comorbid conditions like hypertension or renal impairment.
Lack of Large-Scale Global Clinical Trials
The evidence base for Compound Glycyrrhizin Injection, while robust in certain Asian markets, lacks large-scale, randomized controlled trials that meet the rigorous standards of international regulatory bodies like the FDA and EMA. This evidence gap hinders widespread acceptance and adoption in key Western markets.
Expansion into New Therapeutic Applications
Ongoing research is exploring the potential of glycyrrhizin beyond hepatology, including its anti-viral and anti-cancer properties. Positive results in these areas could open substantial new market segments and drive significant future growth for the injection formulation.
Growth in Emerging Markets
Rising healthcare expenditure, increasing awareness of liver diseases, and growing adoption of traditional and complementary medicines in regions such as Latin America, the Middle East, and Africa present significant untapped opportunities for market penetration and sales growth.
Development of Combination Therapies
There is a strong opportunity for pharmaceutical companies to develop and commercialize fixed-dose combinations of Compound Glycyrrhizin with other hepatoprotective agents. Such combinations could enhance therapeutic outcomes and offer a competitive edge in the crowded liver disease treatment market.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Intravenous Injection stands as the leading segment, primarily due to its rapid onset of action and high bioavailability, which is critical for treating acute liver conditions. This administration method is often preferred in hospital emergency rooms and intensive care units for its quick therapeutic effect. The convenience and established clinical protocols for intravenous injections support its dominant position, while the intravenous drip format is typically reserved for more controlled, longer-duration infusion therapies in specific patient care settings. |
| By Application |
|
Hospital Pharmacy is the leading application segment, as Compound Glycyrrhizin Injection is predominantly administered in a clinical setting under medical supervision for serious hepatic disorders. Hospitals have the necessary infrastructure and professional staff to handle intravenous administration, manage patient responses, and treat potential adverse effects. Retail pharmacies play a more supplementary role, often involved in the supply chain for follow-up or specific outpatient care, while the 'Others' category may include specialized clinics and long-term care facilities. |
| By End User |
|
Hospitals constitute the dominant end-user segment due to the critical nature of the conditions treated with this injection, which require round-the-clock monitoring and advanced medical infrastructure. The high patient inflow for liver-related ailments and the ability to conduct comprehensive diagnostic and therapeutic procedures solidify the hospital's leading role. Specialty clinics focus on gastroenterology and hepatology also utilize this therapy, particularly for specialized patient management, while Ambulatory Surgical Centers may administer it for specific short-stay procedures. |
| By Distribution Channel |
|
Direct Tender is the leading distribution channel, as large-volume purchases by hospital groups and public health systems through tender processes are common for pharmaceutical injectables. This channel ensures bulk supply, cost-effectiveness, and streamlined procurement for major healthcare providers. Wholesalers and distributors play a crucial role in reaching a broader network of smaller hospitals and clinics, while retail sales are a smaller component, typically catering to outpatient prescriptions or smaller healthcare facilities with different procurement needs. |
| By Therapeutic Use |
|
Hepatitis Treatment is the foremost therapeutic application, driving significant demand for Compound Glycyrrhizin Injection due to its recognized efficacy in managing liver inflammation and improving liver function parameters in various forms of hepatitis. The segment for Liver Protection & Detoxification is also substantial, as the injection is used proactively in cases of drug-induced or toxic liver damage. Its anti-inflammatory properties further support use in managing certain Allergy & Dermatological Conditions, although this represents a more niche application compared to its core hepatology uses. |
A Consolidating Market Led by Established Chinese Pharmaceutical Giants
The global Compound Glycyrrhizin Injection market exhibits a competitive structure characterized by the dominance of a few key Chinese manufacturers. In 2024, the top five players collectively accounted for a significant share of the global revenue, underscoring a consolidated market landscape. The market leadership is anchored by companies such as Shanxi PUDE Pharmaceutical and CSPC OUYI Pharmaceutical, which have established strong production capabilities and distribution networks, particularly within the Asia-Pacific region which represents the largest market. These leading players benefit from extensive experience in the production of hepatoprotective drugs and have secured a substantial portion of hospital procurement contracts. Their competitive strategies often revolve around ensuring consistent product quality, scaling production to meet demand, and navigating the complex regulatory environment for pharmaceutical injections in key markets like China.
Beyond the market leaders, a cohort of other significant players contributes to the competitive dynamics, often by focusing on specific regional markets or niche applications. Companies like Xi'an Lijun Pharmaceutical and Beijing Kawin Technology Share-Holding have carved out sustainable positions through specialized formulations and targeted marketing. Other manufacturers, including North China Pharmaceutical, Cisen Pharmaceutical, and Harbin Medisan Pharmaceutical, compete on factors such as price competitiveness and reliability in supply chains. The market also sees participation from firms like Reyoung Pharmaceutical and Chengdu Easton Bio Pharmaceuticals, which continue to innovate and seek growth opportunities in emerging segments, ensuring a vibrant and competitive environment despite the concentration of market share at the top.
List of Key Compound Glycyrrhizin Injection Companies ProfiledShanxi PUDE Pharmaceutical
CSPC OUYI Pharmaceutical
North China Pharmaceutical
Harbin Medisan Pharmaceutical
Anhui Hongye Pharmaceutical
Chengdu Easton Bio Pharmaceuticals
Nanjing Sanhome Pharmaceutical
Zhejiang Conba Pharmaceutical
Jilin Province Huinan Changlong Bio-pharmacy
Guangzhou Baiyunshan Mingxing Pharmaceutical
The global Compound Glycyrrhizin Injection market is on a trajectory of steady growth, projected to expand at a notable CAGR from 2024 to 2032. This growth is underpinned by the increasing clinical application of the drug for treating chronic liver diseases and its anti-inflammatory properties. The market's valuation is set to increase from millions to significantly higher millions by the end of the forecast period. Geographically, while the United States represents a major established market, China is rapidly emerging as a key growth engine, with its market size estimated to reach multi-million dollars, reflecting the rising healthcare expenditure and liver disease prevalence in the region.
Other TrendsDominance of Intravenous Injection and Hospital Pharmacy Channels
Market segmentation reveals clear preferences in administration and distribution. The Intravenous Injection segment is anticipated to reach a multi-million dollar valuation, demonstrating a higher growth rate compared to alternative methods like intravenous drip. This preference is linked to the need for precise and rapid drug delivery in clinical settings. Correspondingly, the Hospital Pharmacy segment continues to hold the dominant share of the market by application. This is attributed to the requirement for professional administration and monitoring of injectable formulations, ensuring that a significant portion of sales is concentrated within hospital networks.
Consolidated Competitive Landscape with Strategic DevelopmentsThe competitive environment is characterized by a degree of consolidation, with the top five manufacturers accounting for a substantial portion of global revenue. Key players, including Shanxi PUDE Pharmaceutical, Beijing Kawin Technology Share-Holding, and CSPC OUYI Pharmaceutical, are central to the market's dynamics. These companies are actively engaged in strategic initiatives such as capacity expansion, mergers, and acquisitions to strengthen their market positions. Continuous product development and efforts to comply with stringent regulatory standards across different regions are critical trends shaping the competitive strategies of these leading firms.
Regional Analysis: Compound Glycyrrhizin Injection MarketNorth America
The North American market for Compound Glycyrrhizin Injection is notably smaller and more niche compared to Asia-Pacific. Growth is primarily constrained by stringent regulatory scrutiny from the FDA, which requires extensive clinical trials for botanical drug approvals, a process that is costly and time-consuming. There is also a different therapeutic paradigm, with a stronger focus on synthetic pharmaceuticals for liver diseases. However, a growing interest in integrative medicine and natural products among a segment of the population and healthcare providers presents a potential avenue for gradual market development, likely through specialized clinics and complementary therapy channels rather than mainstream adoption.
Europe
Europe presents a moderately developing market, characterized by a cautious yet increasing acceptance of phytotherapeutic agents. The European Medicines Agency maintains rigorous standards for herbal medicinal products, creating a high barrier to entry. Market growth is most visible in countries like Germany, where there is a tradition of using herbal medicines. Prescription patterns are influenced by a growing body of clinical research supporting the hepatoprotective effects of glycyrrhizin. Adoption is primarily within specialized gastroenterology and hepatology practices, with market penetration varying significantly between Western and Eastern European countries.
South America
The South American market is emerging, with potential driven by a growing awareness of liver health and an increasing prevalence of liver diseases. However, the market faces challenges related to economic volatility and fragmented healthcare infrastructure, which can limit consistent access to newer therapies. Brazil and Argentina show the most promise, with some incorporation of herbal medicines into public health discussions. Market growth is expected to be slow, reliant on educational initiatives to build physician awareness and on the demonstration of cost-effectiveness for public health systems.
Middle East & Africa
This region represents a nascent market for Compound Glycyrrhizin Injections. Adoption is currently very limited, with market dynamics heavily influenced by economic disparities and varying levels of healthcare development. The Gulf Cooperation Council countries, with their more advanced medical infrastructure, may show the earliest signs of adoption, potentially importing the product for use in private hospitals. Across Africa, access is severely constrained by healthcare budget limitations and a primary focus on infectious diseases, making specialized hepatoprotective injectables a very low priority in most national health agendas.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device manufacturers
Healthcare providers and hospital systems
Contract research organizations
Investors and policy makers
-> Global Compound Glycyrrhizin Injection market was valued at USD 346.8 million in 2024 and is expected to reach USD 451.2 million by 2032.
-> Key players include Shanxi PUDE Pharmaceutical, CSPC OUYI Pharmaceutical, Beijing Kawin Technology Share-Holding, Cisen Pharmaceutical, and North China Pharmaceutical, among others.
-> Key growth drivers include rising prevalence of liver disorders, increasing hepatitis cases, and demand for hepatoprotective therapies.
-> China is the dominant market, while North America shows steady growth.
-> Emerging trends include intravenous drip formulations and expansion of hospital pharmacy distribution channels.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates